What are the side effects of Lenmeldy (atidarsagene autotemcel)? how much do you know

On March 18, 2024, Lenmeldy(atidarsagene autotemcel) was approved by theFDA, bringing a new therapeutic hope to pediatric patients with presymptomatic late infant (PSLI), presymptomatic early adolescent (PSEJ), or early symptomatic early juvenile metachromatic leukodystrophy (MLD). However, while focusing on its efficacy, we cannot ignore its side effects.

A variety of side effects are common in children receivingLenmeldy. The incidence of fever accompanied by low neutrophil count is as high as 85%. Neutrophils are an important line of defense for the immune system, and their reduced number makes patients extremely vulnerable to infection threats. Fever is a response of the body to fight infection. The incidence of intraoral inflammation reaches 77%, which can cause pain and discomfort in the patient's mouth, affecting eating and daily communication. Respiratory tract infections are also relatively common, with 54% of children experiencing such problems, which undoubtedly increases the suffering of patients and the difficulty of treatment.

Side effects such as rash, device-related infections, other viral infections, simple fever, gastroenteritis, and liver enlargement also occurred from time to time, with incidence rates of 33%, 31%, 28%, 21%, 21%, and 18% respectively. These side effects not only affect the patient's quality of life, but may also interfere with the treatment process.

In addition to the obvious side effects mentioned above,Lenmeldy can also cause some laboratory abnormalities. D-dimer elevation occurred in 67% of patients, which may indicate abnormalities in the coagulation and fibrinolytic systems in the body. The incidence of neutropenia was 28%, further weakening the patient's immune function. The incidence of elevated liver enzymes was 23%, which means that the liver may have suffered a certain degree of damage.

UnderstandingThese side effects of Lenmeldy are important for patients and their families. During the treatment process, it is necessary to pay close attention to the patient's physical condition. Once any abnormality occurs, the doctor should be communicated in time so that appropriate measures can be taken to ensure the safety and effectiveness of the treatment.

Reference link:https://www.drugs.com/lenmeldy.html